Zacks.com on MSN54m
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue EstimatesNektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback